Targeting AKT for cancer therapy
Shariati, Maryam, Meric-Bernstam, Funda
Published in Expert opinion on investigational drugs (02.11.2019)
Published in Expert opinion on investigational drugs (02.11.2019)
Get more information
Journal Article
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Rizzo, Alessandro, Ricci, Angela Dalia
Published in Expert opinion on investigational drugs (03.06.2022)
Published in Expert opinion on investigational drugs (03.06.2022)
Get more information
Journal Article
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
Rizzo, Alessandro, Dadduzio, Vincenzo, Ricci, Angela Dalia, Massari, Francesco, Di Federico, Alessandro, Gadaleta-Caldarola, Gennaro, Brandi, Giovanni
Published in Expert opinion on investigational drugs (03.04.2022)
Published in Expert opinion on investigational drugs (03.04.2022)
Get more information
Journal Article
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
Di Federico, Alessandro, Rizzo, Alessandro, Carloni, Riccardo, De Giglio, Andrea, Bruno, Riccardo, Ricci, Dalia, Brandi, Giovanni
Published in Expert opinion on investigational drugs (03.04.2022)
Published in Expert opinion on investigational drugs (03.04.2022)
Get more information
Journal Article
Do STAT3 inhibitors have potential in the future for cancer therapy?
Wong, Andrea L A, Hirpara, Jayshree L, Pervaiz, Shazib, Eu, Jie-Qing, Sethi, Gautam, Goh, Boon-Cher
Published in Expert opinion on investigational drugs (03.08.2017)
Published in Expert opinion on investigational drugs (03.08.2017)
Get more information
Journal Article
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases
Nicolò, Massimo, Ferro Desideri, Lorenzo, Vagge, Aldo, Traverso, Carlo Enrico
Published in Expert opinion on investigational drugs (04.03.2021)
Published in Expert opinion on investigational drugs (04.03.2021)
Get more information
Journal Article
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Rizzo, Alessandro, Ricci, Angela Dalia, Lanotte, Laura, Lombardi, Lucia, Di Federico, Alessandro, Brandi, Giovanni, Gadaleta-Caldarola, Gennaro
Published in Expert opinion on investigational drugs (03.06.2022)
Published in Expert opinion on investigational drugs (03.06.2022)
Get more information
Journal Article
Targeting inflammation in diabetic nephropathy: a tale of hope
Moreno, Juan Antonio, Gomez-Guerrero, Carmen, Mas, Sebastian, Sanz, Ana Belen, Lorenzo, Oscar, Ruiz-Ortega, Marta, Opazo, Lucas, Mezzano, Sergio, Egido, Jesus
Published in Expert opinion on investigational drugs (02.11.2018)
Published in Expert opinion on investigational drugs (02.11.2018)
Get more information
Journal Article
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
Alkhouri, Naim, Lawitz, Eric, Noureddin, Mazen, DeFronzo, Ralph, Shulman, Gerald I
Published in Expert opinion on investigational drugs (01.02.2020)
Published in Expert opinion on investigational drugs (01.02.2020)
Get more information
Journal Article
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
Rizzo, Alessandro, Cusmai, Antonio, Acquafredda, Silvana, Rinaldi, Lucia, Palmiotti, Gennaro
Published in Expert opinion on investigational drugs (03.06.2022)
Published in Expert opinion on investigational drugs (03.06.2022)
Get more information
Journal Article